logo-loader
viewIntegumen

Integumen soars as it rolls out Labskin test to clone skin of clinical trial volunteers

The company said that the new test would cut the number of volunteers required for trials by 50%, reducing recruitment times and project management costs

Clinical trial
Labskin will also allow for double the number of possible skin tests during trials

Integumen PLC (LON:SKIN) shares soared on Friday after the firm announced the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical trials.

The company said that the new test would cut the number of volunteers required for trials by 50%, reducing recruitment times and project management costs, and that when combined with human volunteers Labskin would allow for double the number of possible skin tests and make them more reliable and accurate.

WATCH: Integumen PLC to make 'transformational' move into clinical trials

The Labskin artificial intelligence (AI) platform would allow clients to receive real-time feedback, Integumen said.

Labskin, much like the name suggests, is laboratory-grown skin that is then used by cosmetic and pharmaceutical companies to test how their products react to human skin.

Gerard Brandon, Integumen’s chief executive, said the new Labskin test would “enhance the margins of medical device and clinical trial organisations on test subjects” and deliver “faster, more reliable and consistent results for their skin care, health care, wound care and pharmaceutical clients” at a lower cost.

In early afternoon, the company’s shares were up 16.4% at 1.9p.

Quick facts: Integumen

Price: 1.9 GBX

AIM:SKIN
Market: AIM
Market Cap: £20.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 nervous, gold higher as second wave concerns resurface

Headlines from the Proactive UK newsroom. FTSE 100 dipped as the rise in coronavirus infections in Germany and China unsettled the market. The index dropped 25 to 6,266. Gold rose to a one month high of US$1,750 per ounce overnight as Asian markets wobbled on the coronavirus scare. Bulls of...

2 weeks, 6 days ago

2 min read